HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BI97D6

inhibits Bcl-2 proteins; has antineoplastic activity

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Barile, Elisa: 1 article (01/2011)
2.	Dahl, Russell: 1 article (01/2011)
3.	Dash, Rupesh: 1 article (01/2011)
4.	Fisher, Paul B: 1 article (01/2011)
5.	Kitada, Shinichi: 1 article (01/2011)
6.	Pellecchia, Maurizio: 1 article (01/2011)
7.	Placzek, William J: 1 article (01/2011)
8.	Reed, John C: 1 article (01/2011)
9.	Rega, Michele F: 1 article (01/2011)
10.	Stebbins, John L: 1 article (01/2011)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2011 - "Moreover, compound (-) BI97D6 displays in vivo efficacy in both a Bcl-2-transgenic mouse model and in a prostate cancer xenograft model in mice. " 01/01/2011 - "In a cellular assay, compound (-) BI97D6 effectively inhibits cell growth in the PC-3 human prostate cancer and H23 human lung cancer cell lines with EC(50) values of 0.22 ± 0.08 and 0.14 ± 0.02 μM, respectively. "
2.	Neoplasms (Cancer) 01/01/2011 - "Therefore, compound (-) BI97D6 represents a promising drug lead for the development of novel apoptosis-based therapies for cancer."
3.	Lymphoma (Lymphomas) 01/01/2011 - "Similarly, compound (-) BI97D6 effectively induces apoptosis in the BP3 human lymphoma cell line in a dose-dependent manner. "
4.	Lung Neoplasms (Lung Cancer) 01/01/2011 - "In a cellular assay, compound (-) BI97D6 effectively inhibits cell growth in the PC-3 human prostate cancer and H23 human lung cancer cell lines with EC(50) values of 0.22 ± 0.08 and 0.14 ± 0.02 μM, respectively. "

Related Therapies and Procedures

1.	Therapeutics